U.S. stock futures declined on Monday as investors await mega-cap earnings from tech giants and other major companies. The market is also bracing for the Federal Reserve's interest rate decision on Wednesday, with markets pricing in a 97.2% likelihood of unchanged rates. Key movers include Baker Hughes (up on strong Q4 results), Sarepta Therapeutics (up on trial completion), and Brand Engagement Network (surging 221% on strategic partnership announcement). Analyst Mohamed El-Erian highlights the '2025 Paradox' of resilient markets amid geopolitical tensions.

Sarepta Therapeutics and Teladoc Health are identified as two stocks likely to continue declining in 2026. Sarepta faces significant headwinds from safety concerns with its flagship DMD treatment Elevidys, which caused patient deaths and led to restricted access. Teladoc Health struggles with slowing revenue growth, mounting losses, and increased competition in the telemedicine space, particularly affecting its BetterHelp platform.

Wall Street traded modestly higher Tuesday with the S&P 500 up 0.4% near 6,900. Strong U.S. GDP data (4.3% annualized growth) prompted traders to scale back Fed rate cut expectations. Novo Nordisk surged 9% following FDA approval of Wegovy in pill form. Precious metals rallied significantly, with silver jumping over 2% to break above $70/ounce (up 140% YTD), gold reaching record highs, and platinum surging 5.5%.

Sarepta Therapeutics experienced a significant stock drop of over 33% after its Phase 3 ESSENCE study for Duchenne muscular dystrophy treatments failed to meet primary endpoints, raising concerns about its drug pipeline and gene therapy safety.

The AAV gene therapy market is projected to grow from $3.85 billion in 2025 to $78.56 billion by 2034, with a 40.1% CAGR. North America leads the market, driven by research investments, technological advancements, and increasing genetic disorder prevalence.

The article analyzes two healthcare stocks, Teladoc and Sarepta Therapeutics, highlighting significant challenges that make them unattractive investment options, including revenue decline, profitability issues, and safety concerns with medical treatments.

Sarepta Therapeutics faces a class action lawsuit alleging misleading investors about safety risks of its ELEVIDYS gene therapy for Duchenne muscular dystrophy, with two patient deaths and FDA investigation leading to significant stock price drops.

The genetic material market is expected to experience substantial growth driven by advancements in gene therapies, personalized medicine, and biopharmaceutical research. North America leads the market in 2024, with Asia Pacific projected to be the fastest-growing region from 2025-2034.

The Schall Law Firm is pursuing a class action lawsuit against Sarepta Therapeutics for allegedly making false and misleading statements about its ELEVIDYS therapy's safety, potential, and revenue outlook between June 2023 and June 2025.

Sarepta Therapeutics faces a securities class-action lawsuit over safety concerns and regulatory setbacks for its gene therapy ELEVIDYS, including two patient deaths and European regulatory rejection.

Rosen Law Firm alerts Sarepta Therapeutics investors about a securities class action lawsuit regarding potential misrepresentations about ELEVIDYS gene therapy's safety risks and trial protocols.

A class action lawsuit has been filed against Sarepta Therapeutics regarding alleged misleading statements about safety risks and side effects of its Duchenne muscular dystrophy drug ELEVIDYS, following a patient death that caused significant stock price drop.